Jie Wang

List of Publications by Citations

39 papers	2,388 citations	12 h-index	44 g-index
44 ext. papers	3,473 ext. citations	6.2 avg, IF	4.15 L-index

#	Paper	IF	Citations
39	Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. *Lancet, The*, **2019**, 393, 1819-1830	40	1272
38	Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer. *Journal of Clinical Oncology*, **2009**, 27, 2653-9	2.2	237
37	Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel. *JAMA Oncology*, **2019**, 5, 696-702	13.4	237
36	Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer. *Journal of Clinical Oncology*, **2012**, 30, 3077-83	2.2	154
35	Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial. *Journal of Thoracic Oncology*, **2019**, 14, 867-875	8.9	141
34	TCR Repertoire Diversity of Peripheral PD-1CD8 T Cells Predicts Clinical Outcomes after Immunotherapy in Patients with Non-Small Cell Lung Cancer. *Cancer Immunology Research*, **2020**, 8, 146-154	12.5	72
33	Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial. *JAMA Oncology*, **2021**, 7, 709-717	13.4	45
32	Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study **2020**, 8,		30
31	Allele Frequency-Adjusted Blood-Based Tumor Mutational Burden as a Predictor of Overall Survival for Patients With NSCLC Treated With PD-(L)1 Inhibitors. *Journal of Thoracic Oncology*, **2020**, 15, 556-567	8.9	27
30	Anlotinib vs placebo as third- or further-line treatment for patients with small cell lung cancer: a randomised, double-blind, placebo-controlled Phase 2 study. *British Journal of Cancer*, **2021**, 125, 366-371	8.7	22
29	Epigenetic alterations are associated with tumor mutation burden in non-small cell lung cancer **2019**, 7, 198		19
28	Transbronchoscopic patient biopsy-derived xenografts as a preclinical model to explore chemorefractory-associated pathways and biomarkers for small-cell lung cancer. *Cancer Letters*, **2019**, 440-441, 180-188	9.9	12
27	Recommendations of individualized medical treatment and common adverse events management for lung cancer patients during the outbreak of COVID-19 epidemic. *Thoracic Cancer*, **2020**, 11, 1752-1757	3.2	12
26	Upfront dose-reduced chemotherapy synergizes with immunotherapy to optimize chemoimmunotherapy in squamous cell lung carcinoma **2020**, 8,		10
25	Metagenome association study of the gut microbiome revealed biomarkers linked to chemotherapy outcomes in locally advanced and advanced lung cancer. *Thoracic Cancer*, **2021**, 12, 66-78	3.2	10
24	EPHA mutation as a predictor of immunotherapeutic efficacy in lung adenocarcinoma **2020**, 8,		9
23	A Phase 2 Study of Tislelizumab in Combination With Platinum-Based Chemotherapy as First-line Treatment for Advanced Lung Cancer in Chinese Patients. *Lung Cancer*, **2020**, 147, 259-268	5.9	9

#		IF	Cit
22	Association between recent oncologic treatment and mortality among patients with carcinoma who are hospitalized with COVID-19: A multicenter study. *Cancer*, **2021**, 127, 437-448	6.4	8
21	Alterations in EGFR and related genes following neo-adjuvant chemotherapy in Chinese patients with non-small cell lung cancer. *PLoS ONE*, **2013**, 8, e51021	3.7	7
20	Refined Stratification Based on Baseline Concomitant Mutations and Longitudinal Circulating Tumor DNA Monitoring in Advanced EGFR-Mutant Lung Adenocarcinoma Under Gefitinib Treatment. *Journal of Thoracic Oncology*, **2020**, 15, 1857-1870	8.9	7
19	A novel tumor mutational burden estimation model as a predictive and prognostic biomarker in NSCLC patients. *BMC Medicine*, **2020**, 18, 232	11.4	7
18	Apatinib, a novel VEGFR inhibitor plus docetaxel in advanced lung adenocarcinoma patients with wild-type EGFR: a phase I trial. *Investigational New Drugs*, **2019**, 37, 731-737	4.3	6
17	Rare case of apatinib acquired resistance induced by point mutation of WRN p.V697F through activation of the PI3K/AKT apoptosis-inhibiting pathway. *Thoracic Cancer*, **2021**, 12, 128-132	3.2	5
16	Influence of adjuvant chemotherapy on survival for patients with stage IB and IIA non-small cell lung cancer. *Thoracic Cancer*, **2021**, 12, 30-39	3.2	4
15	Efficacy and safety of treatment modalities across EGFR selected/unselected populations with non-small cell lung cancer and brain metastases: A systematic review and Bayesian network meta-analysis. *Lung Cancer*, **2021**, 158, 74-84	5.9	4
14	Clinical outcomes and radiation pneumonitis after concurrent EGFR-tyrosine kinase inhibitors and radiotherapy for unresectable stage III non-small cell lung cancer. *Thoracic Cancer*, **2021**, 12, 814-823	3.2	4
13	Brigatinib treated ALK positive lung squamous cell carcinoma after failed chemotherapy: A case report. *Thoracic Cancer*, **2021**, 12, 3273-3276	3.2	3
12	Efficacy and safety of immune checkpoint inhibitor consolidation after chemoradiation in patients of Asian ethnicity with unresectable stage III non-small cell lung cancer: Chinese multicenter report and literature review. *Thoracic Cancer*, **2020**, 11, 2916-2923	3.2	2
11	Individualized model for predicting COVID-19 deterioration in patients with cancer: A multicenter retrospective study. *Cancer Science*, **2021**, 112, 2522-2532	6.9	2
10	Weighting tumor-specific TCR repertoires as a classifier to stratify the immunotherapy delivery in non-small cell lung cancers. *Science Advances*, **2021**, 7,	14.3	2
9	Effectiveness of anlotinib in patients with small-cell lung cancer and pleural effusion: Subgroup analysis from a randomized, multicenter, phase II study. *Thoracic Cancer*, **2021**, 12, 3039-3045	3.2	2
8	Development and validation of a prediction model using molecular marker for long-term survival in unresectable stage III non-small cell lung cancer treated with chemoradiotherapy.. *Thoracic Cancer*, **2021**,	3.2	2
7	Optimal Initial Time Point of Local Radiotherapy for Unresectable Lung Adenocarcinoma: A Retrospective Analysis on Overall Arrangement of Local Radiotherapy in Advanced Lung Adenocarcinoma.. *Frontiers in Oncology*, **2022**, 12, 793190	5.3	1
6	Reporting quality of randomized, controlled trials evaluating immunotherapy in lung cancer. *Thoracic Cancer*, **2021**, 12, 2732-2739	3.2	1
5	Anlotinib for patients with small cell lung cancer and baseline liver metastases: A post hoc analysis of the ALTER 1202 trial.. *Cancer Medicine*, **2021**,	4.8	1

4	Evolution and genotypic characteristics of small cell lung cancer transformation in non-small cell lung carcinomas. *Journal of the National Cancer Center*, **2021**, 1, 153-153		0
3	Identification and validation of tissue or ctDNA PTPRD phosphatase domain deleterious mutations as prognostic and predictive biomarkers for immune checkpoint inhibitors in non-squamous NSCLC. *BMC Medicine*, **2021**, 19, 239	11.4	0
2	Lung cancer and intraocular metastasis in gestation: Clinical experiences of a rare case. *Thoracic Cancer*, **2020**, 11, 2723-2726	3.2	0
1	Predictive Value of Max's Giant Associated Protein Mutation in Outcomes of Lung Adenocarcinoma Patients Treated With Immune Checkpoint Inhibitors. *Frontiers in Cell and Developmental Biology*, **2021**, 9, 728647	5.7	